Letrozole - Novartis

Drug Profile

Letrozole - Novartis

Alternative Names: CGP 20267; CGS 20267; Femara

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novartis
  • Developer M. D. Anderson Cancer Center; National Cancer Institute (USA); Novartis; University of Colorado at Denver
  • Class Antineoplastics; Nitriles; Small molecules; Triazoles
  • Mechanism of Action Aromatase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Breast cancer
  • Phase II Endometrial cancer; Fallopian tube cancer; Leiomyosarcoma; Ovarian cancer; Peritoneal cancer
  • Discontinued Delayed puberty; Endometriosis; Female infertility

Most Recent Events

  • 18 Sep 2018 Eli Lilly plans a phase II trial for Endometrial cancer (Combination therapy, Recurrent) in the US in October 2018 (NCT03675893)
  • 24 Jun 2018 Biomarkers information updated
  • 21 Nov 2017 Phase-I/II clinical trials in Breast cancer (Combination therapy, Late-stage disease, Metastatic disease, Inoperable/Unresectable) in USA (PO) (NCT03054363)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top